Similar Items: Cost–Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan
- Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan
- Successful Treatment of IL‐23 Inhibitor–Refractory Nail Psoriasis With Deucravacitinib: A Case Report
- New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review
- A Dermal Plaque on the Arm
- Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II
- Pingueculitis in psoriasis patient on secukinumab – An unreported adverse event